Anti-inflammatory effect of a selective IκB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 3, 2010, Pages 172-181

  Rajendrasozhan, Saravanan ^a   Hwang, Jae Woong ^a   Yao, Hongwei ^a   Kishore, Nandini ^b   Rahman, Irfan ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

COPD; IKK2 inhibitor; Inflammation; NF B; Tobacco smoke

Indexed keywords

8 [5 CHLORO 2 (4 METHYLPIPERAZIN 1 YL)ISONICOTINAMIDO] 1 (4 FLUOROPHENYL) 4,5 DIHYDRO 1H BENZO[G]INDAZOLE 3 CARBOXAMIDE; CIGARETTE SMOKE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B KINASE; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHA 408; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DNA BINDING; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; I-KAPPA B KINASE; INDAZOLES; INFLAMMATION MEDIATORS; ISONICOTINIC ACIDS; LIPOPOLYSACCHARIDES; LUNG; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SMOKING;

EID: 77950340431     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.01.002     Document Type: Article

References (46)

1. Burchfiel C.M., Marcus E.B., Curb J.D., Maclean C.J., Vollmer W.M., Johnson L.R., et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 151 (1995) 1778-1785
2. Saetta M. Airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 (1999) S17-S20
3. Barnes P.J., and Kleinert S. COPD-a neglected disease. Lancet 364 (2004) 564-565
4. Halbert R.J., Natoli J.L., Gano A., Badamgarav E., Buist A.S., and Mannino D.M. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28 (2006) 523-532
5. Barnes P.J., and Hansel T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364 (2004) 985-996
6. Ito K., Caramori G., and Adcock I.M. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321 (2007) 1-8
7. Birrell M.A., Wong S., Hardaker E.L., Catley M.C., McCluskie K., Collins M., et al. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 69 (2006) 1791-1800
8. Medicherla S., Fitzgerald M.F., Spicer D., Woodman P., Ma J.Y., Kapoun A.M., et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 324 (2008) 921-929
9. Newton R., Holden N.S., Catley M.C., Oyelusi W., Leigh R., Proud D., et al. Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther 321 (2007) 734-742
10. Adcock I.M., Chung K.F., Caramori G., and Ito K. Kinase inhibitors and airway inflammation. Eur J Pharmacol 533 (2006) 118-132
11. de Boer W.I., Yao H., and Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis 2 (2007) 205-228
12. Yao H., de Boer W., and Rahman I. Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD. Curr Respir Med Rev 4 (2008) 57-68
13. Di Stefano A., Caramori G., Oates T., Capelli A., Lusuardi M., Gnemmi I., et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 20 (2002) 556-563
14. Caramori G., Romagnoli M., Casolari P., Bellettato C., Casoni G., Boschetto P., et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58 (2003) 348-351
15. Rajendrasozhan S., Yang S.R., Edirisinghe I., Yao H., Adenuga D., and Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 10 (2008) 799-811
16. Rajendrasozhan S., Yang S.R., Kinnula V.L., and Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177 (2008) 861-870
17. Rahman I., and Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28 (2006) 219-242
18. Szulakowski P., Crowther A.J., Jimenez L.A., Donaldson K., Mayer R., Leonard T.B., et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 (2006) 41-50
19. Baldwin Jr. A.S. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107 (2001) 3-6
20. Barnes P.J. Cytokine modulators as novel therapies for airway disease. Eur Respir J Suppl 34 (2001) 67s-77s
21. Marwick J.A., Kirkham P.A., Stevenson C.S., Danahay H., Giddings J., Butler K., et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 31 (2004) 633-642
22. Li Z.W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189 (1999) 1839-1845
23. Yao H., Edirisinghe I., Yang S.R., Rajendrasozhan S., Kode A., Caito S., et al. Genetic ablation of NADPH oxidase enhances susceptibility to cigarette smoke-induced lung inflammation and emphysema in mice. Am J Pathol 172 (2008) 1222-1237
24. O'Connell M.A., Bennett B.L., Mercurio F., Manning A.M., and Mackman N. Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem 273 (1998) 30410-30414
25. Hawiger J., Veach R.A., Liu X.Y., Timmons S., and Ballard D.W. IkappaB kinase complex is an intracellular target for endotoxic lipopolysaccharide in human monocytic cells. Blood 94 (1999) 1711-1716
26. Li Q., Van Antwerp D., Mercurio F., Lee K.F., and Verma I.M. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284 (1999) 321-325
27. Kishore N., Sommers C., Mathialagan S., Guzova J., Yao M., Hauser S., et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem 278 (2003) 32861-32871
28. Coish P., Wickens P., and Lowinger T. Small molecule inhibitors of IKK kinase activity. Expert Opin Ther Pat 16 (2006) 1-12
29. Mbalaviele G., Sommers C.D., Bonar S.L., Mathialagan S., Schindler J.F., Guzova J.A., et al. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. J Pharmacol Exp Ther 329 (2009) 14-25
30. Sommers C.D., Thompson J.M., Guzova J.A., Bonar S.L., Rader R.K., Mathialagan S., et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther 330 (2009) 377-388
31. Chiang P.C., Kishore N.N., and Thompson D.C. Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IkappaB kinase-2 (IKK-2) target safety and efficacy. J Pharm Sci 99 (2010) 1278-1287
32. Yao H., Yang S.R., Edirisinghe I., Rajendrasozhan S., Caito S., Adenuga D., et al. Disruption of p21 attenuates lung inflammation induced by cigarette smoke, LPS, and fMLP in mice. Am J Respir Cell Mol Biol 39 (2008) 7-18
33. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl (2002) S81-S96
34. Yamamoto Y., and Gaynor R.B. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 29 (2004) 72-79
35. Chen L.F., and Greene W.C. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 5 (2004) 392-401
36. Brown V., Elborn J.S., Bradley J., and Ennis M. Dysregulated apoptosis and NFkappaB expression in COPD subjects. Respir Res 10 (2009) 24-35
37. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., and Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 347-360
38. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004) 574-580
39. Edwards M.R., Bartlett N.W., Clarke D., Birrell M., Belvisi M., and Johnston S.L. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 121 (2009) 1-13
40. Kim C.S., Kawada T., Kim B.S., Han I.S., Choe S.Y., Kurata T., et al. Capsaicin exhibits anti-inflammatory property by inhibiting IkB-a degradation in LPS-stimulated peritoneal macrophages. Cell Signal 15 (2003) 299-306
41. Adenuga D., and Rahman I. Oxidative Stress, Histone Deacetylase and Corticosteroid Resistance in Severe Asthma and COPD. Curr Respir Med Rev 3 (2007) 57-68
42. De Stefano D., De Rosa G., Maiuri M.C., Ungaro F., Quaglia F., Iuvone T., et al. Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 60 (2009) 33-40
43. Karimi K., Sarir H., Mortaz E., Smit J.J., Hosseini H., De Kimpe S.J., et al. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res 7 (2006) 66-78
44. Doukas J., Eide L., Stebbins K., Racanelli-Layton A., Dellamary L., Martin M., et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 328 (2009) 758-765
45. Kent L.M., Smyth L.J., Plumb J., Clayton C.L., Fox S.M., Ray D.W., et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-78-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). J Pharmacol Exp Ther 328 (2009) 458-468
46. Fox J.C., and Fitzgerald M.F. The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD. Curr Opin Pharmacol 9 (2009) 231-242